次世代がん診断装置の世界市場 - 2025年～2033年

次世代がん診断装置の世界市場は、2024年に181億2,000万米ドルに達し、2033年には611億4,000万米ドルに達すると予測され、予測期間2025年～2033年のCAGRは15.2%で成長する見込みです。

次世代がん診断装置（NGCD）は、分子レベルでがんを同定し特徴付けるために使用される高度な技術と手順です。これらの装置は、特に次世代シーケンシング（NGS）などの洗練された手法を使用し、腫瘍遺伝学に関する詳細な洞察を提供することで、早期の同定、カスタマイズされた治療レジメン、より良い患者の転帰を可能にします。次世代がん診断装置は、がん細胞の遺伝物質を評価するためにハイスループットシーケンス技術を使用する機器および技術のコレクションです。NGSでは、数百万個のDNA断片の同時シーケンスが可能であり、多くの種類のがんに関連する遺伝子変異、変化、バイオマーカーの検出が可能です。この能力は、しばしば単一または限られた遺伝子標的に焦点を当てる従来の方法と比較して、診断プロセスを大幅に向上させる。

次世代がん診断装置に対する需要の増加が、予測期間中の市場を牽引する要因です。がん患者数の増加は、がんの状態を分析し、それに応じて治療を設計するために、がん検査やがん腫瘍の包括的なゲノム・プロファイリングに対する需要を増加させる。例えば、2023年1月にnih.govが発表した記事によると、2023年には米国で195万8310人の新規がん患者と60万9820人のがん死亡者が発生すると予測されています。前立腺がんの罹患率は、20年にわたる減少の後、2014年から2019年にかけて毎年3%増加し、99,000人の新規症例が追加されることになります。

市場力学：

促進要因と抑制要因

次世代がん診断機器に対する需要の増加

次世代がん診断機器に対する需要の増加は、世界の次世代がん診断機器市場の成長における重要な要因になると予想されます。次世代がん診断装置の世界市場は、がんの有病率の上昇、技術の進歩、最近の製品の発売と承認、戦略的パートナーシップ、人々の意識の高まりなどを主な要因として、大幅な拡大が見込まれています。

がん患者の増加は、がんの状態を分析し、それに応じて治療を設計するために、がん検査とがん腫瘍の包括的なゲノム・プロファイリングの需要を増加させる。そのため、がん患者数の増加が次世代がん診断装置に対する需要を高めています。さらに、世界がん研究基金によると、非黒色腫皮膚がん（NMSC）を含めると、2022年のがん患者数は19,976,499人です。NMSCを除くと、2022年には世界中で18,741,966人のがん患者が発生します。このうち、男性が956万6,825人、女性が917万5,141人です。さらに、IARCによれば、2022年に新たに発生するがん（非黒色腫皮膚がん［NMSC］を含む）は2,000万件に迫り、がんによる死亡者（NMSCを含む）は970万人に上ります。推計によると、生涯にがんに罹患するのは男性または女性の約5人に1人で、死亡するのは男性の約9人に1人、女性の約12人に1人です。肺がんは2022年に最も多く診断されたがんで、約250万人が新たに罹患し、これは全世界のがんの8人に1人（全世界のがんの12.4％）にあたる。

さらに、技術の進歩はNGCDの能力を著しく向上させ、医療用途に有益なものにしています。自動化システムと迅速なポイント・オブ・ケア検査の統合により、診断ラボの業務が簡素化され、その結果、ターンアラウンドタイムが短縮され、効率が向上しました。例えば、2024年8月、ラボラトリーオートメーションとイノベーションの世界的リーダーであるBeckman Coulter Life Sciencesは、DNAシーケンシングとアレイベース技術のリーダーであるIlluminaと提携し、少ないタッチポイントでより迅速な結果をもたらす腫瘍学研究への有望な新しいアプローチを提供します。Beckman Coulter Life SciencesのBiomek NGeniuSシステム用Illumina TruSight Oncology 500 DNA/RNA検査は、腫瘍サンプルの包括的ゲノムプロファイリングのための革新的な自動化アプローチです。

先端診断技術の高コスト

高度な診断技術にかかる高額な費用などの要因が、世界の次世代がん診断機器市場を阻害すると予想されます。これらの費用は、特に資源が限られているヘルスケアシステムにおいて、普及の大きな障害となる可能性があります。例えば、次世代シークエンシング（NGS）検査の費用は、必要とされる分析の複雑さや範囲によって、1検査あたり1,000ドルから10,000ドルと大きく異なります。このような経済的負担は、特に医療資金が限られている中低所得国において、ヘルスケア提供者がこのような最新の診断機器に投資する意欲を失わせる可能性があります。さらに、NGCD技術を導入するために必要な初期投資は多額です。施設は、150,000ドルから500,000ドルもするNGSプラットフォームなどの高度な機器を入手しなければならないです。こうした高コストが顧客の装置購入を制限し、市場の妨げとなっています。

このレポートの詳細- サンプル請求

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
  • 次世代がん診断機器の需要増加
  • 抑制要因
  • 高度な診断技術の高コスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 償還分析
• 特許分析
• SWOT分析
• DMIの見解

第6章 技術別

• 次世代シーケンシング
• qPCRとマルチプレックス
• ラボオンチップ（LOAC）
• タンパク質マイクロアレイ
• DNAマイクロアレイ

第7章 がんの種類別

• 肺がん
• 乳がん
• 大腸がん
• 子宮頸がん
• その他

第8章 用途別

• バイオマーカー開発
• CTC分析
• プロテオーム解析
• エピジェネティック解析
• 遺伝子解析

第9章 エンドユーザー別

• 病院
• がん調査機関
• 診断センター

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
    • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• GE HealthCare
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Illumina, Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Koninklijke Philips N.V
• QIAGEN
• Agilent Technologies, Inc.
• Abbott
• Thermo Fisher Scientific Inc.
• BD

第13章 付録

The global next-generation cancer diagnostic devices market reached US$ 18.12 billion in 2024 and is expected to reach US$ 61.14 billion by 2033, growing at a CAGR of 15.2% during the forecast period 2025-2033.

Next Generation Cancer Diagnostic Devices (NGCD) are advanced technologies and procedures used to identify and characterize cancer at the molecular level. These devices use sophisticated methods, particularly Next-Generation Sequencing (NGS), to provide detailed insights into tumor genetics, allowing for earlier identification, customized treatment regimens, and better patient outcomes. Next Generation Cancer Diagnostic Devices are a collection of instruments and technology that use high-throughput sequencing techniques to evaluate genetic material from cancer cells. NGS enables the simultaneous sequencing of millions of DNA fragments, allowing for the detection of genetic mutations, changes, and biomarkers linked to many types of cancer. This capability significantly enhances the diagnostic process compared to traditional methods, which often focus on single or limited genetic targets.

The increasing demand for next-generation cancer diagnostic devices is the driving factor that drives the market over the forecast period. The increasing number of cancer cases increases the demand for cancer testing and the comprehensive genomic profiling of the cancer tumor to analyze the state of the cancer and design the treatment accordingly. For instance, according to an article published by nih.gov in January 2023, in 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases.

Market Dynamics: Drivers & Restraints

Increasing demand for next-generation cancer diagnostic devices

The increasing demand for next-generation cancer diagnostic devices is expected to be a significant factor in the growth of the global next-generation cancer diagnostic devices market. The global next-generation cancer diagnostic devices market is poised for significant expansion, owing mostly to the rising prevalence of cancer, technological advancements, recent product launches and approvals, strategic partnerships, and increasing awareness among people.

The increasing number of cancer cases increases the demand for cancer testing and the comprehensive genomic profiling of the cancer tumor to analyze the state of the cancer and design the treatment accordingly. So, the increasing number of cancer cases increases the demand for next-generation cancer diagnostic devices. Moreover, according to the World Cancer Research Fund, including non-melanoma skin cancer (NMSC) there were 19,976,499 cancer cases in 2022. When NMSC was excluded, this number dropped to 18,741,966 cancer cases around the world in 2022. Of these, 9,566,825 were in men and 9,175,141 in women. Moreover, according to IARC, There were close to 20 million new cases of cancer in the year 2022 (including nonmelanoma skin cancers [NMSCs]) alongside 9.7 million deaths from cancer (including NMSC). The estimates suggest that approximately one in five men or women develop cancer in a lifetime, whereas around one in nine men and one in 12 women die from it. Lung cancer was the most frequently diagnosed cancer in 2022, responsible for almost 2.5 million new cases, or one in eight cancers worldwide (12.4% of all cancers globally).

Furthermore, advancements in technology have significantly enhanced the capabilities of NGCDs, making them beneficial in medical applications. The integration of automated systems and rapid point-of-care testing has simplified operations in diagnostic labs, resulting in faster turnaround times and increased efficiency. For instance, in August 2024, Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, collaborated with Illumina, a leader in DNA sequencing and array-based technologies, to offer a promising new approach to oncology research that delivers faster results with fewer touch points. Beckman Coulter Life Sciences' Illumina TruSight Oncology 500 DNA/RNA test for the Biomek NGeniuS System is an innovative automated approach for comprehensive genomic profiling of tumor samples.

High costs of advanced diagnostics technologies

Factors such as high costs of advanced diagnostics technologies are expected to hamper the global next-generation cancer diagnostic devices market. These expenditures can be a significant impediment to widespread adoption, especially in healthcare systems with limited resources. For example, the cost of next-generation sequencing (NGS) tests can vary greatly, ranging from $1,000 to $10,000 per test, depending on the complexity and scope of the analysis needed. This financial burden may discourage healthcare providers from investing in these modern diagnostic equipment, particularly in low- and middle-income countries where healthcare funding is limited. Furthermore, the initial investment needed to install NGCD technologies is significant. Facilities must obtain advanced equipment, such as NGS platforms, which can cost anywhere from $150,000 to $500,000. These high costs restrict the customers from buying the devices and hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global next-generation cancer diagnostic devices market is segmented based on technology, cancer type, application, end-user, and region.

Next-generation Sequencing segment is expected to dominate the global next-generation cancer diagnostic devices market share

The Next-generation Sequencing segment is anticipated to dominate the global next-generation cancer diagnostic devices market owing to the technology's capacity to give thorough genetic profiling, which is critical for understanding cancer biology driving individualized treatment regimens, and increasing the number of cancer cases. NGS allows for the simultaneous study of numerous genes, identifying uncommon mutations, fusion genes, and structural alterations that are crucial for proper cancer diagnosis and treatment selection.

One of the primary technological developments sustaining the NGS segment's growth is the remarkable drop in sequencing costs. Whole genome sequencing costs have dropped from tens of thousands of dollars to roughly $1,000, making it more affordable for therapeutic applications. This cost reduction has been made possible by advances in sequencing technology, such as better reagents and automated platforms that boost throughput while lowering operational costs. Furthermore, advances in bioinformatics tools have improved data analytic skills, enabling more efficient interpretation of complicated genomic data. These enhancements allow healthcare practitioners to provide NGS as a standard diagnostic tool, further consolidating its commercial position.

For instance, in October 2023, Philips has collaborated with Quibim, an imaging biomarker specialist, to create next-generation AI-based imaging and reporting solutions specifically for magnetic resonance (MR) prostate screenings. This collaboration intends to improve prostate cancer detection and treatment by combining Philips' superior MR imaging technology with Quibim's AI-powered QP-Prostate software. The major goal is to automate prostate gland segmentation in magnetic resonance images, which would not only standardize reporting but also give clinicians with key quantitative insights required for accurate diagnosis and individualized treatment programs.

Geographical Analysis

North America is expected to hold a significant position in the global next-generation cancer diagnostic devices market share

North America is anticipated to hold a significant portion of the global next-generation cancer diagnostic devices market owing to the rising prevalence of cancer, technological advancements, recent product launches and approvals, strategic partnerships, and increasing awareness. The higher prevalence of cancer in North America also contributes to the increased demand for advanced diagnostic solutions. Rising awareness of cancer screening and early detection fuels this demand, prompting healthcare practitioners to explore novel solutions such as Next Generation Sequencing (NGS) and other advanced diagnostic technologies. As cancer rates rise, the need for effective diagnostics expands, strengthening North America's position as the dominant market.

For instance, according to an article published by the National Institute of Health, in January 2024, in 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both adjuvant and metastatic settings. However, these gains are threatened by increasing incidence for 6 of the top 10 cancers.

Technological advancements like the incorporation of AI and machine learning into diagnostic processes is yet another key technical achievement. AI systems can quickly and accurately scan massive volumes of genomic data, assisting physicians in identifying actionable mutations that inform individualized therapy options. This collaboration between NGS and AI not only simplifies workflows but also improves patient outcomes by allowing for more accurate therapy methods. For instance, in September 2023, Pillar Biosciences, Inc., the leader in Decision Medicine, announced the global launch of oncoReveal Core LBx, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a solution for liquid biopsy-based pan-cancer tumor profiling.

Asia Pacific is growing at the fastest pace in the global next-generation cancer diagnostic devices market

One of the key drivers of this expansion is Asia Pacific's huge and expanding population, which contributes to an increased incidence of oncological disorders. As the population grows, so does the number of people at risk for cancer, resulting in a greater demand for sophisticated diagnostic tools. Countries such as China and India have unusually high rates of cancer incidence as a result of lifestyle changes, urbanization, and aging populations. This demographic transition pushes healthcare systems to prioritize early detection and effective treatment choices, accelerating the deployment of next-generation cancer diagnostic technologies.

For instance, according to the National Institute of Health, the expected number of cancer cases in India for 2022 is 14,61,427 (crude rate: 100.4 per 100,000). In India, one out of every nine people is likely to develop cancer over his or her lifetime. Males and females were most likely to develop lung and breast cancer, respectively. The increasing number of cancer cases increases the demand for cancer testing and the comprehensive genomic profiling of the cancer tumor to analyze the state of the cancer and design the treatment accordingly. So, the increasing number of cancer cases makes this region the fastest growing region.

Competitive Landscape

The major global players in the global next-generation cancer diagnostic devices market include GE HealthCare, Illumina, Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V, QIAGEN, Agilent Technologies, Inc., Abbott, Thermo Fisher Scientific Inc., BD among others.

Emerging Players

PathAI, Karius, and OncoOne among others

Key Developments

• In May 2024, Foundation Medicine Inc. announced the U.S. launch of FoundationOneRNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes. FoundationOne RNA enables reporting of fusions in all solid tumors and may be valuable for detecting fusions in certain cancers, such as non-small cell lung cancer (NSCLC), pancreatic cancer, cholangiocarcinoma, sarcoma, thyroid cancer, and bladder cancer.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global next-generation cancer diagnostic devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Technology
• 3.2. Snippet by Cancer Type
• 3.3. Snippet by Application
• 3.4. Snippet by End-User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
  • 4.1.2. Increasing Demand for Next-Generation Cancer Diagnostic Devices
  • 4.1.3. Restraints
  • 4.1.4. High Costs of Advanced Diagnostics Technologies
  • 4.1.5. Opportunity
  • 4.1.6. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Technology

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 6.1.2. Market Attractiveness Index, By Technology
• 6.2. Next-generation Sequencing*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. qPCR & Multiplexing
• 6.4. Lab-on-a-chip (LOAC)
• 6.5. Protein Microarrays
• 6.6. DNA Microarrays

7. By Cancer Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 7.1.2. Market Attractiveness Index, By Cancer Type
• 7.2. Lung Cancer*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Breast Cancer
• 7.4. Colorectal Cancer
• 7.5. Cervical Cancer
• 7.6. Others

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Biomarker Development*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. CTC Analysis
• 8.4. Proteomic Analysis
• 8.5. Epigenetic Analysis
• 8.6. Genetic Analysis

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Cancer Research Institutes
• 9.4. Diagnostic Centres

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  • 10.2.8. The U.S.
  • 10.2.9. Canada
  • 10.2.10. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Product Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  • 10.3.9. Germany
  • 10.3.10. UK
  • 10.3.11. France
  • 10.3.12. Italy
  • 10.3.13. Spain
    • 10.3.13.1. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  • 10.4.8. Brazil
  • 10.4.9. Argentina
  • 10.4.10. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  • 10.5.8. China
  • 10.5.9. India
  • 10.5.10. Japan
  • 10.5.11. South Korea
  • 10.5.12. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. GE HealthCare*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Illumina, Inc.
• 12.3. Novartis AG
• 12.4. F. Hoffmann-La Roche Ltd
• 12.5. Koninklijke Philips N.V
• 12.6. QIAGEN
• 12.7. Agilent Technologies, Inc.
• 12.8. Abbott
• 12.9. Thermo Fisher Scientific Inc.
• 12.10. BD

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us